🔴 HCW Biologics is trading 6% down as the decline’s cause remains unclear

HCW Biologics is trading at $1.04, down 5.70%, with the cause of the decline unclear.

• On November 5, HCW Biologics announced up to $10.0 million in debt financing: $3.0 million received at November 4 closing, with another $7.0 million available subject to conditions.
• Funding is intended to support the Phase 1 HCW9302 study; the company expects to establish a Phase 2 dose in Q1 2027.
• No source linked the financing to the intraday decline, and biotech-sector gains offered no same-direction explanation.